Humalog

RSS

insulin lispro

Authorised
This medicine is authorised for use in the European Union.

Overview

Humalog is a range of insulin medicines used to treat patients who have diabetes and need insulin to keep their blood glucose (sugar) level controlled, including patients whose diabetes has just been diagnosed.

Humalog medicines contain the active substance insulin lispro on its own or combined with protamine to make it longer acting:

  • Humalog (100 units/ml): standard-strength insulin lispro (fast-acting);
  • Humalog (200 units/ml): high-strength insulin lispro (fast-acting);
  • Humalog Mix25 (100 units/ml): 25% insulin lispro (fast-acting) and 75% insulin lispro protamine (longer-acting);
  • Humalog Mix50 (100 units/ml): 50% insulin lispro (fast-acting) and 50% insulin lispro protamine (longer-acting).

This EPAR was last updated on 05/10/2021

Authorisation details

Product details
Name
Humalog
Agency product number
EMEA/H/C/000088
Active substance
insulin lispro
International non-proprietary name (INN) or common name
insulin lispro
Therapeutic area (MeSH)
Diabetes Mellitus
Anatomical therapeutic chemical (ATC) code
  • A10AB04
  • A10AD04
Publication details
Marketing-authorisation holder
Eli Lilly Nederland B.V.
Revision
34
Date of issue of marketing authorisation valid throughout the European Union
30/04/1996
Contact address

Papendorpseweg 83
3528 BJ Utrecht
The Netherlands

Product information

07/09/2021 Humalog - EMEA/H/C/000088 - N/0192

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Humalog is also indicated for the initial stabilisation of diabetes mellitus.

Assessment history

How useful was this page?

Add your rating